What is Mekinist nad how is it used?
Mekinist is a prescription medicine used:
Mekinist should not be used to treat people who already have received a BRAF inhibitor for treatment of their melanoma, and it did not work or is no longer working.
What are the possible side effects of Mekinist?
Mekinist may cause serious side effects, including:
Tell your healthcare provider if you get a skin rash or acne that bothers you or worsens.
Tell your healthcare provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including:
The most common side effects of Mekinist when taken alone include:
The most common side effects of Mekinist when taken with dabrafenib in people with melanoma that hasspread to other parts of the body or cannot be removed by surgery include:
The most common side effects of Mekinist when taken with dabrafenib to help prevent melanoma from coming back after the cancer has been removed by surgery include:
The most common side effects of Mekinist when taken with dabrafenib in people with NSCLC include:
Mekinist can cause new or worsening high blood pressure (hypertension).
Your healthcare provider should check your blood pressure during treatment with Mekinist. Call your healthcare provider right away if you develop high blood pressure, your blood pressure worsens, or you have severe headache, lightheadedness, blurry vision, or dizziness.
Mekinist may cause fertility problems in females. This could affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.
These are not all the possible side effects of Mekinist.
Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Novartis Pharmaceuticals Corporation at 1-888-669-6682.
MEKINIST® is indicated, as a single agent in BRAF-inhibitor treatment-naive patients or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test [see DOSAGE AND ADMINISTRATION].
MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection [see DOSAGE AND ADMINISTRATION].
MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test [see DOSAGE AND ADMINISTRATION].
MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options [see DOSAGE AND ADMINISTRATION].
The recommended dosage of MEKINIST is 2 mg orally taken once daily, as a single agent or in combination with dabrafenib, until disease progression or unacceptable toxicity. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.
The recommended dosage of MEKINIST is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity for up to 1 year. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.
The recommended dosage of MEKINIST is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.
The recommended dosage of MEKINIST is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.
SKU-NINGFPKVHPGZVARIANT | SELLER | PRICE | QUANTITY |
---|
What is Mekinist nad how is it used?
Mekinist is a prescription medicine used:
Mekinist should not be used to treat people who already have received a BRAF inhibitor for treatment of their melanoma, and it did not work or is no longer working.
What are the possible side effects of Mekinist?
Mekinist may cause serious side effects, including:
Tell your healthcare provider if you get a skin rash or acne that bothers you or worsens.
Tell your healthcare provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including:
The most common side effects of Mekinist when taken alone include:
The most common side effects of Mekinist when taken with dabrafenib in people with melanoma that hasspread to other parts of the body or cannot be removed by surgery include:
The most common side effects of Mekinist when taken with dabrafenib to help prevent melanoma from coming back after the cancer has been removed by surgery include:
The most common side effects of Mekinist when taken with dabrafenib in people with NSCLC include:
Mekinist can cause new or worsening high blood pressure (hypertension).
Your healthcare provider should check your blood pressure during treatment with Mekinist. Call your healthcare provider right away if you develop high blood pressure, your blood pressure worsens, or you have severe headache, lightheadedness, blurry vision, or dizziness.
Mekinist may cause fertility problems in females. This could affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.
These are not all the possible side effects of Mekinist.
Call your doctor for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Novartis Pharmaceuticals Corporation at 1-888-669-6682.
MEKINIST® is indicated, as a single agent in BRAF-inhibitor treatment-naive patients or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test [see DOSAGE AND ADMINISTRATION].
MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection [see DOSAGE AND ADMINISTRATION].
MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test [see DOSAGE AND ADMINISTRATION].
MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options [see DOSAGE AND ADMINISTRATION].
The recommended dosage of MEKINIST is 2 mg orally taken once daily, as a single agent or in combination with dabrafenib, until disease progression or unacceptable toxicity. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.
The recommended dosage of MEKINIST is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity for up to 1 year. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.
The recommended dosage of MEKINIST is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.
The recommended dosage of MEKINIST is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.